Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Gene Therapy Agent

Gene therapy (AAV vector) · Gene replacement

Phase 1/2 Most advanced trial (none active)
1 Registered trials

What is Gene Therapy Agent?

Gene Therapy Agent is an AAV2-based viral vector carrying the human AADC gene, injected into the bilateral putamen by stereotactic surgery. It is studied in aromatic L-amino acid decarboxylase (AADC) deficiency, an inherited disorder.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Gene therapy (AAV vector)
Mechanism
Gene replacement
Therapy area
Metabolic, Neurology
In trials of
PTCT
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT01395641 Phase 1/2 Aromatic L-amino Acid Decarboxylase (AADC) Deficiency Completed PTCT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Aromatic L-amino Acid Decarboxylase (AADC) Deficiency

Sources

Updated Oct 25, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.